Search Results

Zanubrutinib

Zanubrutinib is indicated for the treatment of adult patients with:

Tazemetostat

Tazemetostat is a methyltransferase inhibitor indicated for the treatment of:

Relevance of ubiquitin dependent proteolysis in Diffuse Large B-cell lymphoma

The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large B-cell Lymphoma (DLBCL). Our studies leverage the expertise in the molecular modeling of the UPS in the pathogenesis of DLBCL utilizing mouse models, patient derived xenotransplant (PDX) and cell lines. Our goal is the understanding of how genetic mutations contribute to disease development, progression and therapeutic outcome.

Meet The Researcher: Dr. Christopher R. Flowers

Novel Immunotherapy Combinations in Relapsed, Refractory Mantle Cell Lymphoma

We are evaluating two parallel clinical trials with synergistic immunotherapies in mantle cell lymphoma (MCL), including 1) tafasitamab and lenalidomide and 2) glofitamab and lenalidomide. We will investigate how these treatments impact the MCL immune microenvironment and mediate anti-tumor immune responses, and will correlate these changes with outcome. Our goal is to develop safe, effective, and "off-the-shelf" immunotherapies to improve outcomes for patients with relapsed, refractory MCL.

World-Renowned Chef & Cancer Survivor Cooks for a Cure

Shortly before Steve McHugh and his wife moved to San Antonio in 2010, the rising star chef was diagnosed with non-Hodgkin lymphoma and spent a year undergoing eight rounds of chemotherapy.

“Chemotherapy was a real roller coaster – I experienced insomnia, constipation and dizzy spells. There were times I would not sleep for three to four days,” he said.

Detection and treatment of Adult T cell leukemia/lymphoma in the premalignant stage.

Clonally expanded T cells carrying somatic mutations circulate in the premalignant phase of Adult T cell leukemia/lymphoma (ATL). We will develop capture-sequencing of recurrent ATL-driver mutations for use as a diagnostic tool for the detection/characterization of ATL-like clones in individuals with high risk of ATL, and, in an aligned clinical study, we will test whether a novel monoclonal antibody (targeting C-C chemokine receptor 4) can eradicate these high-risk cells.

Immunotherapies on a Roll at #ASH20

More than three years after the first chimeric antigen receptor (CAR) T-cell therapy achieved U.S. Food and Drug Administration (FDA) approval, the revolutionary approach that has upended blood cancer treatment continues to generate excitement.

Discovery and therapeutic targeting of novel mechanisms driving Double Hit Lymphomas

Double-hit lymphoma (DHL) is an aggressive form of diffuse large B-cell lymphoma (DLBCL) defined by co-occuring MYC and BCL2 rearrangements. DHL has been linked to very poor outcomes when treated with R-CHOP chemotherapy. Effective treatments to prevent treatment failure remain a critical unmet need. This proposal will develop novel, mechanism-based therapeutic regimens for DHL that overcome chemotherapy resistance and defective immune surveillance to improve outcomes.

2018 Nobel Prize in Physiology or Medicine: Unleashing the Immune System

The Nobel Prize in Physiology or Medicine has been awarded today to two scientists whose groundbreaking work led to the development of a class of immunotherapies called checkpoint inhibitors that work by releasing the brakes on the immune system.

Autologous CD22 CAR T cell Therapy for the Treatment of non-Hodgkin Lymphoma

CD19 targeting chimeric antigen receptor (CAR) T cell therapies (CAR19) are effective treatments for patients with non-Hodgkin Lymphoma (NHL), however, the majority of these patients will relapse. We have now evaluated a CD22 targeting CAR T cell therapy (CAR22) in patients who have large B cell lymphoma who have relapsed after CAR19 therapy and found that this therapy is both safe and effective resulting in a high rate of durable complete responses.

Development of mutant GTPase-specific degraders for peripheral T cell lymphoma treatment

This project aims to develop targeted therapies against peripheral T cell lymphoma (PTCL), a diverse group of aggressive blood cancers with poor clinical outcomes. This project is tightly relevant to cancer control and treatment, promising to advance our understanding on how blood cancers initiate and progress, and lead to new therapeutics for the treatment of peripheral T cell lymphoma (PTCL). We will develop targeted therapeutics to engage an oncogenic RHOA GTPase mutant to treat PTCL and other types of tumors with similar genetic backgrounds.

Finding New Approaches to Immunotherapy

New Drug Approval Expands Options for Patients with Rare Marginal Zone Lymphoma and Advanced Follicular Lymphoma

New Drug Approval Expands Options For Patients with Rare Marginal Zone Lymphoma and Advanced Follicular Lymphoma

EXPANDING FEDERAL RESOURCES FOR BLOOD CANCER RESEARCH

Learn how The Leukemia & Lymphoma Society (LLS) played a key role in restoring research for all blood cancers as a priority funding area for 2018.

 

When we think of the federal government’s investments in medical research, we almost always think of the National Institutes of Health (NIH), our nation’s medical research agency. For more than a century, NIH has paved the way for scientific breakthroughs that are helping people live longer, healthier lives.

Reflections from the #ASH19 Meeting

As the 61st Annual ASH (American Society of Hematology) Meeting and Exhibition winds down here in Orlando, here are some thoughts on where things stand in the world of blood cancers.

CAR-T Immunotherapy Showing Positive Results

This week, positive data from a Kite Pharma CAR-T immunotherapy clinical trial was released showing that more than one-third of refractory aggressive non-Hodgkin lymphoma (NHL) patients in the study showed no signs of the disease after six months.

Since 2015, The Leukemia & Lymphoma Society has been funding this study through its collaboration with Kite Pharma, a biotechnology company focused on immunotherapy.

Exploiting tumor-immune dynamics to inform curative combination therapy for follicular lymphoma

Follicular lymphoma is a common form of blood cancer, affecting 15,000 new patients annually in the United States, but it remains incurable with conventional treatments. Bispecific antibodies represent a new class of therapies that engage the immune system to attack lymphoma cells and have shown promising effectiveness in inducing remissions in patients with this disease, but even they are unlikely to be curative.

Non-Hodgkin Lymphoma: Know Your Subtype

Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)

Burlington and The Leukemia and Lymphoma Surprise a Young Survivor

Treating Aggressive Non-Hodgkin Lymphomas (NHL)